Amneal Pharmaceuticals (AMRX) Research & Development (2017 - 2026)
Amneal Pharmaceuticals has reported Research & Development over the past 9 years, most recently at $34.8 million for Q4 2025.
- For Q4 2025, Research & Development fell 35.84% year-over-year to $34.8 million; the TTM value through Dec 2025 reached $186.2 million, down 2.38%, while the annual FY2025 figure was $186.2 million, 2.38% down from the prior year.
- Research & Development for Q4 2025 was $34.8 million at Amneal Pharmaceuticals, down from $63.4 million in the prior quarter.
- Over five years, Research & Development peaked at $63.4 million in Q3 2025 and troughed at $34.8 million in Q4 2025.
- A 5-year average of $46.9 million and a median of $48.1 million in 2021 define the central range for Research & Development.
- Biggest five-year swings in Research & Development: soared 47.67% in 2024 and later tumbled 35.84% in 2025.
- Year by year, Research & Development stood at $51.9 million in 2021, then decreased by 19.21% to $41.9 million in 2022, then grew by 9.97% to $46.1 million in 2023, then grew by 17.75% to $54.3 million in 2024, then plummeted by 35.84% to $34.8 million in 2025.
- Business Quant data shows Research & Development for AMRX at $34.8 million in Q4 2025, $63.4 million in Q3 2025, and $48.0 million in Q2 2025.